The European Union has come out against several drug companies, saying that they were costing billions of dollars by delaying generics from making it to market. Some of the methods of delaying generics included paying off companies selling the generics and also amassing thousands of patents on a single drug in order to sue generic companies for violations of one or more patents. Article [1]
Links:
[1] http://www.nytimes.com/2008/11/29/business/worldbusiness/29drugs.html?_r=1&ref=health